Lantheus (LNTH) Stock Forecast, Price Target & Predictions
LNTH Stock Forecast
Lantheus stock forecast is as follows: an average price target of $146.25 (represents a 26.68% upside from LNTH’s last price of $115.45) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
LNTH Price Target
The average price target for Lantheus (LNTH) is $146.25 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $175.00 to $120.00. This represents a potential 26.68% upside from LNTH's last price of $115.45.
LNTH Analyst Ratings
According to 6 Wall Street analysts, Lantheus's rating consensus is 'Buy'. The analyst rating breakdown for LNTH stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Lantheus Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 03, 2024 | Ed Ridley-Day | Redburn Partners | $175.00 | $106.47 | 64.37% | 51.58% |
| Aug 01, 2024 | David Turkaly | JMP Securities | $125.00 | $104.83 | 19.24% | 8.27% |
| Jul 12, 2024 | Anthony Petrone | Mizuho Securities | $165.00 | $123.62 | 33.47% | 42.92% |
| Nov 15, 2022 | - | Leerink Partners | $120.00 | $57.25 | 109.61% | 3.94% |
| Aug 05, 2022 | - | Leerink Partners | $110.00 | $76.25 | 44.26% | -4.72% |
The latest Lantheus stock forecast, released on Sep 03, 2024 by Ed Ridley-Day from Redburn Partners, set a price target of $175.00, which represents a 64.37% increase from the stock price at the time of the forecast ($106.47), and a 51.58% increase from LNTH last price ($115.45).
Lantheus Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $175.00 | $155.00 |
| Last Closing Price | $115.45 | $115.45 | $115.45 |
| Upside/Downside | -100.00% | 51.58% | 34.26% |
In the current month, the average price target of Lantheus stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Lantheus's last price of $115.45. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 01, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Jul 25, 2024 | B. Riley | Buy | Buy | Hold |
| Jul 10, 2024 | JMP Securities | Outperform | Outperform | Hold |
| May 03, 2024 | Truist Financial | Market Outperform | Market Outperform | Hold |
| May 03, 2024 | Mizuho Securities | Underperform | Underperform | Hold |
| Apr 18, 2024 | B. Riley | Buy | Buy | Hold |
| Feb 23, 2024 | Cowen & Co. | Underperform | Underperform | Hold |
| Feb 23, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Nov 15, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Lantheus's last stock rating was published by Cowen & Co. on Sep 16, 2024. The company gave LNTH a "Buy" rating, the same as its previous rate.
Lantheus Financial Forecast
Lantheus Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $319.95M | $321.70M | $300.78M | $263.17M | $239.29M | $223.72M | $208.88M | $129.56M | $102.07M | $101.06M | $92.51M | $94.15M | $88.54M |
| Avg Forecast | $624.31M | $596.23M | $561.51M | $528.70M | $499.96M | $476.76M | $447.63M | $429.06M | $427.75M | $395.00M | $393.30M | $382.74M | $385.72M | $371.71M | $382.12M | $349.25M | $339.56M | $314.26M | $305.78M | $280.68M | $244.74M | $228.01M | $204.40M | $165.30M | $111.78M | $97.13M | $94.77M | $87.24M | $92.23M | $91.96M |
| High Forecast | $624.31M | $596.23M | $561.51M | $528.70M | $499.96M | $476.76M | $447.63M | $429.06M | $427.75M | $395.00M | $393.30M | $382.74M | $385.72M | $379.19M | $382.12M | $349.25M | $343.01M | $319.28M | $305.78M | $280.68M | $244.74M | $228.01M | $204.40M | $165.30M | $111.78M | $97.13M | $94.77M | $87.24M | $92.23M | $91.96M |
| Low Forecast | $624.31M | $596.23M | $561.51M | $528.70M | $499.96M | $476.76M | $447.63M | $429.06M | $427.75M | $395.00M | $393.30M | $382.74M | $385.72M | $366.68M | $382.12M | $349.25M | $324.60M | $311.98M | $305.78M | $280.68M | $244.74M | $228.01M | $204.40M | $165.30M | $111.78M | $97.13M | $94.77M | $87.24M | $92.23M | $91.96M |
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.05% | 1.07% | 1.08% | 1.05% | 1.09% | 1.26% | 1.16% | 1.05% | 1.07% | 1.06% | 1.02% | 0.96% |
Lantheus's average Quarter revenue forecast for Dec 23 based on 6 analysts is $339.56M, with a low forecast of $324.60M, and a high forecast of $343.01M. LNTH's average Quarter revenue forecast represents a 6.13% increase compared to the company's last Quarter revenue of $319.95M (Sep 23).
Lantheus EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $112.36M | $143.93M | $-6.11M | $-173.07M | $98.40M | $75.35M | $70.72M | $-27.28M | $-5.93M | $-16.97M | $25.18M | $8.36M | $3.88M |
| Avg Forecast | $38.48M | $36.75M | $34.61M | $32.59M | $30.82M | $29.39M | $27.59M | $26.45M | $26.37M | $24.35M | $24.24M | $23.59M | $23.78M | $22.91M | $23.55M | $65.80M | $20.93M | $19.37M | $18.85M | $59.82M | $-17.47M | $14.05M | $12.60M | $63.98M | $6.89M | $5.99M | $5.84M | $5.38M | $5.69M | $5.67M |
| High Forecast | $38.48M | $36.75M | $34.61M | $32.59M | $30.82M | $29.39M | $27.59M | $26.45M | $26.37M | $24.35M | $24.24M | $23.59M | $23.78M | $23.37M | $23.55M | $78.96M | $21.14M | $19.68M | $18.85M | $71.78M | $-13.98M | $14.05M | $12.60M | $76.77M | $6.89M | $5.99M | $5.84M | $5.38M | $5.69M | $5.67M |
| Low Forecast | $38.48M | $36.75M | $34.61M | $32.59M | $30.82M | $29.39M | $27.59M | $26.45M | $26.37M | $24.35M | $24.24M | $23.59M | $23.78M | $22.60M | $23.55M | $52.64M | $20.01M | $19.23M | $18.85M | $47.86M | $-20.97M | $14.05M | $12.60M | $51.18M | $6.89M | $5.99M | $5.84M | $5.38M | $5.69M | $5.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.80% | 7.64% | -0.10% | 9.90% | 7.00% | 5.98% | 1.11% | -3.96% | -0.99% | -2.91% | 4.68% | 1.47% | 0.68% |
6 analysts predict LNTH's average Quarter EBITDA for Dec 23 to be $20.93M, with a high of $21.14M and a low of $20.01M. This is -81.37% lower than Lantheus's previous annual EBITDA (Sep 23) of $112.36M.
Lantheus Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $131.96M | $94.13M | $-2.81M | $-119.19M | $61.23M | $43.06M | $42.96M | $-40.22M | $-13.41M | $-26.66M | $9.01M | $-3.41M | $-6.39M |
| Avg Forecast | $176.59M | $169.44M | $160.49M | $152.12M | $129.93M | $-80.37M | $119.93M | $93.09M | $150.23M | $116.38M | $124.71M | $113.97M | $115.26M | $109.87M | $129.17M | $39.71M | $101.03M | $93.41M | $92.46M | $36.10M | $-25.76M | $58.66M | $49.63M | $38.61M | $11.77M | $4.47M | $3.49M | $56.75M | $841.21K | $-4.10M |
| High Forecast | $176.59M | $169.44M | $160.49M | $152.12M | $129.93M | $-80.37M | $119.93M | $93.09M | $150.23M | $116.38M | $124.71M | $113.97M | $115.26M | $121.77M | $129.19M | $47.65M | $108.54M | $95.53M | $96.60M | $43.32M | $-20.61M | $58.66M | $49.63M | $46.33M | $11.77M | $4.47M | $3.49M | $68.10M | $841.21K | $-4.10M |
| Low Forecast | $176.59M | $169.44M | $160.49M | $152.12M | $129.93M | $-80.37M | $119.93M | $93.09M | $150.23M | $116.38M | $124.71M | $113.97M | $115.26M | $105.67M | $129.16M | $31.77M | $94.21M | $89.16M | $88.32M | $28.88M | $-30.91M | $58.66M | $49.63M | $30.89M | $11.77M | $4.47M | $3.49M | $45.40M | $841.21K | $-4.10M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.41% | 1.02% | -0.08% | 4.63% | 1.04% | 0.87% | 1.11% | -3.42% | -3.00% | -7.64% | 0.16% | -4.06% | 1.56% |
Lantheus's average Quarter net income forecast for Dec 23 is $101.03M, with a range of $94.21M to $108.54M. LNTH's average Quarter net income forecast represents a -23.44% decrease compared to the company's last Quarter net income of $131.96M (Sep 23).
Lantheus SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $73.14M | $62.61M | $55.89M | $66.62M | $49.17M | $60.09M | $57.94M | $81.95M | $45.74M | $60.81M | $30.31M | $26.54M | $29.83M |
| Avg Forecast | $198.82M | $189.88M | $178.82M | $168.37M | $159.22M | $151.83M | $142.55M | $136.64M | $136.22M | $125.79M | $125.25M | $121.89M | $122.84M | $118.37M | $121.69M | $53.55M | $108.14M | $100.08M | $97.38M | $48.68M | $52.50M | $72.61M | $65.09M | $52.07M | $35.60M | $30.93M | $30.18M | $27.78M | $29.37M | $29.28M |
| High Forecast | $198.82M | $189.88M | $178.82M | $168.37M | $159.22M | $151.83M | $142.55M | $136.64M | $136.22M | $125.79M | $125.25M | $121.89M | $122.84M | $120.76M | $121.69M | $64.26M | $109.24M | $101.68M | $97.38M | $58.42M | $63.00M | $72.61M | $65.09M | $62.48M | $35.60M | $30.93M | $30.18M | $27.78M | $29.37M | $29.28M |
| Low Forecast | $198.82M | $189.88M | $178.82M | $168.37M | $159.22M | $151.83M | $142.55M | $136.64M | $136.22M | $125.79M | $125.25M | $121.89M | $122.84M | $116.77M | $121.69M | $42.84M | $103.37M | $99.35M | $97.38M | $38.95M | $42.00M | $72.61M | $65.09M | $41.65M | $35.60M | $30.93M | $30.18M | $27.78M | $29.37M | $29.28M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.73% | 0.64% | 1.15% | 1.27% | 0.68% | 0.92% | 1.11% | 2.30% | 1.48% | 2.01% | 1.09% | 0.90% | 1.02% |
Lantheus's average Quarter SG&A projection for Dec 23 is $108.14M, based on 6 Wall Street analysts, with a range of $103.37M to $109.24M. The forecast indicates a 47.85% rise compared to LNTH last annual SG&A of $73.14M (Sep 23).
Lantheus EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.93 | $1.38 | $-0.04 | $-1.74 | $0.89 | $0.63 | $0.63 | $-0.59 | $-0.20 | $-0.39 | $0.13 | $-0.05 | $-0.10 |
| Avg Forecast | $2.50 | $2.40 | $2.27 | $2.15 | $1.84 | $-1.14 | $1.70 | $1.32 | $2.13 | $1.65 | $1.77 | $1.61 | $1.63 | $1.56 | $1.83 | $1.54 | $1.43 | $1.32 | $1.31 | $1.29 | $0.96 | $0.83 | $0.70 | $0.46 | $0.17 | $0.06 | $0.05 | $-0.01 | $0.01 | $-0.06 |
| High Forecast | $2.50 | $2.40 | $2.27 | $2.15 | $1.84 | $-1.14 | $1.70 | $1.32 | $2.13 | $1.65 | $1.77 | $1.61 | $1.63 | $1.72 | $1.83 | $1.56 | $1.54 | $1.35 | $1.37 | $1.36 | $0.96 | $0.83 | $0.70 | $0.46 | $0.17 | $0.06 | $0.05 | $-0.01 | $0.01 | $-0.06 |
| Low Forecast | $2.50 | $2.40 | $2.27 | $2.15 | $1.84 | $-1.14 | $1.70 | $1.32 | $2.13 | $1.65 | $1.77 | $1.61 | $1.63 | $1.50 | $1.83 | $1.53 | $1.33 | $1.26 | $1.25 | $1.22 | $0.96 | $0.83 | $0.70 | $0.46 | $0.17 | $0.06 | $0.05 | $-0.01 | $0.01 | $-0.06 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.46% | 1.05% | -0.03% | -1.81% | 1.07% | 0.90% | 1.37% | -3.54% | -3.16% | -7.89% | -13.00% | -4.20% | 1.72% |
According to 6 Wall Street analysts, Lantheus's projected average Quarter EPS for Dec 23 is $1.43, with a low estimate of $1.33 and a high estimate of $1.54. This represents a -25.85% decrease compared to LNTH previous annual EPS of $1.93 (Sep 23).
Lantheus Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IRWD | Ironwood Pharmaceuticals | $4.19 | $11.67 | 178.52% | Buy |
| PCRX | Pacira BioSciences | $16.45 | $40.00 | 143.16% | Hold |
| DVAX | Dynavax | $11.79 | $24.50 | 107.80% | Buy |
| AQST | Aquestive Therapeutics | $5.15 | $9.50 | 84.47% | Buy |
| ANIP | ANI Pharmaceuticals | $56.01 | $79.00 | 41.05% | Buy |
| AMPH | Amphastar Pharmaceuticals | $50.59 | $66.00 | 30.46% | Buy |
| CTLT | Catalent | $58.69 | $76.40 | 30.18% | Hold |
| ALKS | Alkermes | $26.59 | $34.38 | 29.30% | Hold |
| COLL | Collegium Pharmaceutical | $32.72 | $41.50 | 26.83% | Buy |
| LNTH | Lantheus | $115.45 | $146.25 | 26.68% | Buy |
| NBIX | Neurocrine Biosciences | $120.53 | $147.70 | 22.54% | Buy |
| AVDL | Avadel Pharmaceuticals | $14.86 | $17.80 | 19.78% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
LNTH Forecast FAQ
Is Lantheus a good buy?
Yes, according to 6 Wall Street analysts, Lantheus (LNTH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of LNTH's total ratings.
What is LNTH's price target?
Lantheus (LNTH) average price target is $146.25 with a range of $120 to $175, implying a 26.68% from its last price of $115.45. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Lantheus stock go up soon?
According to Wall Street analysts' prediction for LNTH stock, the company can go up by 26.68% (from the last price of $115.45 to the average price target of $146.25), up by 51.58% based on the highest stock price target, and up by 3.94% based on the lowest stock price target.
Can Lantheus stock reach $200?
LNTH's average twelve months analyst stock price target of $146.25 does not support the claim that Lantheus can reach $200 in the near future.
What are Lantheus's analysts' financial forecasts?
Lantheus's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.85B (high $1.85B, low $1.85B), average EBITDA is $114.25M (high $114.25M, low $114.25M), average net income is $262.59M (high $262.59M, low $262.59M), average SG&A $590.23M (high $590.23M, low $590.23M), and average EPS is $3.72 (high $3.72, low $3.72). LNTH's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $2.31B (high $2.31B, low $2.31B), average EBITDA is $142.44M (high $142.44M, low $142.44M), average net income is $658.65M (high $658.65M, low $658.65M), average SG&A $735.88M (high $735.88M, low $735.88M), and average EPS is $9.33 (high $9.33, low $9.33).
Did the LNTH's actual financial results beat the analysts' financial forecasts?
Based on Lantheus's last annual report (Dec 2022), the company's revenue was $935.06M, beating the average analysts forecast of $842.45M by 10.99%. Apple's EBITDA was $34.49M, missing the average prediction of $73.16M by -52.85%. The company's net income was $28.07M, missing the average estimation of $121.13M by -76.83%. Apple's SG&A was $233.83M, missing the average forecast of $242.27M by -3.49%. Lastly, the company's EPS was $0.41, missing the average prediction of $2.95 by -86.12%. In terms of the last quarterly report (Sep 2023), Lantheus's revenue was $319.95M, beating the average analysts' forecast of $314.26M by 1.81%. The company's EBITDA was $112.36M, beating the average prediction of $19.37M by 480.03%. Lantheus's net income was $131.96M, beating the average estimation of $93.41M by 41.27%. The company's SG&A was $73.14M, missing the average forecast of $100.08M by -26.92%. Lastly, the company's EPS was $1.93, beating the average prediction of $1.32 by 45.87%